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Background: Peroxisome proliferator-activated receptors (PPARs, including alpha, beta and gamma subtypes) and
their agonists have a protective role in treatment of central nervous system (CNS) diseases. The present study
was designed to investigate the expression changes of PPAR-alpha, −beta, −gamma and NF-kappa B in the
hippocampus of rats with global cerebral ischemia/reperfusion injury (GCIRI) after treatment with agonists
or antagonists of PPAR-gamma.
Methods: A rat GCIRI model was established by occlusion of bilateral common carotid arteries and cervical vena
retransfusion. GW9662 (5 μg), a selective PPAR- gamma antagonist, was intraventricularly injected at 0.5 h before
GCIR; Rosiglitazone (0.8, 2.4 and 7.2 mg/kg), a selective PPAR- gamma agonist, was injected intraperitoneally at
1 h before GCIRI. The expression changes of PPAR-alpha, −beta and -gamma at mRNA and protein levels were
detected by RT-PCR and western blotting. The changes of spatial learning and memory (SLM) functions were
assessed by using a Morris water maze; the pathohistological changes of hippocampal neurons were evaluated by
hematoxylin-eosin (HE) staining; the contents of IL-1, IL-6, IL-10 and TNF-alpha, and the NF- kappa B expression were
measured by enzyme-linked immunosorbent assay (ELISA) and immunohistochemical staining. The superoxide
dismutase (SOD) activity and malondialdehyde (MDA) content were also detected.
Results: The SLM function and hippocampal neurons were significantly impaired after the occurrence of GCIRI. The
MDA, IL-1, IL-6, IL-10, TNF-alpha content and expression of PPARs increased significantly, but the SOD activity and
NF-kappa B expression were weakened in the hippocampus. Rosiglitazone treatment significantly protected rats
from SLM function impairment and neuron death, and resulted in higher expressions of SOD activity and NF-kappa B,
but lower contents of MDA and inflammatory factors. After treatment with rosiglitazone or GW9662, no significant
change in PPAR-alpha or -beta expression was detected.
Conclusions: Rosiglitazone, a PPAR-gamma agonist, plays a protective role in hippocampal neuron damage of GCIRI
rats by inhibiting the oxidative stress response and inflammation. The activation or antagonism of PPAR-gamma did
not affect the expression of PPAR-alpha or -beta, indicating that the three subtypes of PPARs act in independent
pathways in the CNS.
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Peroxisome proliferator-activated receptors (PPARs), which
belong to the nuclear receptor family of ligand-activated
transcription factors, were originally described as gene
regulators of various metabolic pathways, such as me-
tabolism, adipogenesis, trophoblast differentiation, cell
migration and inflammation control [1–6]. PPAR-α is
mainly expressed in brown adipose tissues, the liver,
muscles and the kidney; it is mainly involved in regu-
lating lipid metabolism, insulin sensitivity and glucose
homeostasis [7,8]. PPAR-β is expressed all over the body
and participates in embryonic development, implant-
ation, bone formation and lipid metabolism [9,10].
PPAR-γ is mainly expressed in adipose tissues, colonic
epithelia, macrophages, the liver, the spleen and the kid-
ney; it plays an important role in insulin sensitivity, cell
cycle regulation and cell differentiation [11]. In the
past decade, tremendous progress has been made to-
wards understanding the physiological roles of PPARs in
the occurrence and development of many human diseases,
including diabetes, obesity, atherosclerosis, hypertension
and cancer.
Global cerebral ischemia/reperfusion injury (GCIRI)
occurs in patients who are successfully resuscitated from
various clinical conditions such as cardiac arrest, asphyxia
and shock, which are frequently accompanied by in-
flammation and can lead to serious neuronal injury,
and further to neurodegeneration and learning and
memory impairment [12]. Proinflammatory cytokines, such
as interleukin (IL)-1β, IL-6 and tissue necrosis factor
(TNF)-α, have been implicated as important mediators of
injury following cerebral ischemia [13] and contribute to
pathogenesis, exacerbating brain tissue damage following
ischemia/reperfusion (I/R) injury [14].
In addition to regulating metabolism, activation of
PPARs results in anti-inflammation and antioxidative
effects [15]. Intriguingly, recent reports show that acti-
vation of PPARs is helpful in regulating neuronal death in
patients with ischemic brain injury and neurodegenerative
diseases [16–19]. The expression level of PPAR-α genes in
the hippocampus and the improvement of cognitive per-
formance were increased by the reduction of the n-6:n-3
fatty acid ratio [20]. The effects of palmitoylethanolamide
(PEA) on astrocyte activation and neuronal loss and
subsequently the improved neuronal survival in models of
amyloid-β (Aβ) neurotoxicity are dependent on the expres-
sion of PPAR-α [21]. Genetic ablation of PPAR-α in mice
exacerbated the systemic toxicity of 1-methy l-4 -phenyl-
1,2,3,6-tetrahyropyridine (MPTP), while PEA-induced
neuroprotection was partially PPAR-α-dependent [22].
The central administration of PPAR-δ/β agonists signifi-
cantly and dose-dependently attenuated the ischemic brain
damage after reperfusion in rats [23]. GW0742 as an agon-
ist of PPAR-δ/β exerts significant neuroprotective effects inrats with GCIRI via PPAR-δ/β activation and its anti-
inflammation effect [24].
PPAR-γ is the focus among the three PPAR subtypes in
terms of their neuroprotective effects. In animal models of
neurological and cardiovascular diseases, rosiglitazone
prevents neuronal cell death and reduced infarct volume
after ischemia and reperfusion [25]. Thiazolidinediones
(an agonists of PPAR-γ) modulate the maturation and
differentiation of microglia and astrocytes, and inhibit
the production of nitric oxide (NO), pro-inflammatory
cytokines TNF-α, IL-1β and IL-6, and chemokine MCP-1
from microglia and astrocytes [26]. In addition, pioglita-
zone increases the cerebral level of Cu-Zn superoxide dis-
mutase (Cu-Zn SOD) and significantly reduces the infarct
size induced by transient but not permanent MCAO [27].
Intraventricular administration of pioglitazone 24 h before
MCAO significantly reduces the expressions of IL-1,
COX-2 and inducible nitric-oxide synthase (iNOS) in-
duced by inflammation [28]. These results demonstrate
that PPAR-γ agonists have protective effects on focal
cerebral ischaemia-reperfusion injury (IRI), and that
the action mechanisms include inhibition of inflammatory
reaction and oxidative stress. However, those studies focus
on the neuroprotective effect of PPAR-γ in focal ischemia
models, but not on the expression and effect of PPAR-γ in
the GCIRI model.
Four major domains have been identified in PPARs:
A/B, C, D and E/F. Domain C is comprised of about 70
amino acids and encodes the DNA-binding domain
(DBD). Domain E, which is the ligand-binding domain
(LBD), is responsible for ligand specificity and activation
of PPAR binding to the peroxisome proliferator response
element (PPRE) with resultant modulation of gene expres-
sion. In humans, there is about an 86% identity between
PPAR-α and -β and 83% identity between PPAR-α and -γ1
in DBD, and about a 70% identity between PPAR-α and -β
and 68% identity between PPAR-α and -γ1 in LBD [10],
which are similar in humans. However, the sequences of
PPARs have high identity in rats: about an 86% identity
between PPAR-α and -β and 83% identity between PPAR-
α and -γ in DBD, and about a 66% identity between
PPAR-α and -β and 62% identity between PPAR-α and -γ
in LBD. Under such percentages of identity in the struc-
ture among those three isotypes, it has not been character-
ized whether the expression change of PPAR-γ will affect
those of the other subtypes, or whether activation or inhi-
biton of PPAR-γ will affect the expressions of the other
subtypes.
The objectives of the present study are to investigate
whether the PPAR-γ agonist exerts beneficial action on
the memory and learning function by anti-oxidant and
inhibits inflammatory reaction: investigate the expression
of PPARs in the hippocampus of GCIRI rats, to evaluate
the changes of PPAR-α and -β expressions due to agonism
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PPAR isotypes are acting in independent pathways in the
CNS. The results will provide a basis for combination of
PPARs to prevent GCIRI in the clinical setting.
Method
Animals and experimental design
Experiments were approved by the Animal Laboratory
Administrative Center and the Institutional Ethics Commit-
tee at Chongqing Medical University. 84 Sprague–Dawley
(SD) male rats (200–250 g, from the Laboratory Animal
Center of Chongqing Medical University) were subjected to
bilateral carotid artery occlusion. Prior to the artery occlu-
sion, the rats were randomly allocated to the following
groups:
1. Sham group: The animals were subjected to the
same surgical procedures as other groups but the
common carotid arteries were not occluded (n = 12).
2. Ischemia/Reperfusion (I/R) group: The rats received
GCIR (n = 12).
3. 0.8 mg/kg rosiglitazone group: Identical to ischemia
model group, except for receiving rosiglitazone
(a kind gift from Prof. Xi-He Yan from Department
of Medicinal Chemistry of Chongqing Medical
University) 0.8 mg/kg i.p. 1 hour prior to artery
occlusion (n = 12).
4. 2.4 mg/kg rosiglitazone group: Identical to ischemia
model group except for receiving rosiglitazone
2.4 mg/kg i.p. at 1 hour prior to artery occlusion
(n = 12).
5. 7.2 mg/kg rosiglitazone group: Identical to ischemia
model group except for receiving rosiglitazone 7.2 mg/
kg i.p. at 1 hour prior to artery occlusion (n = 12).
6. 7.2 mg/kg rosiglitazone plus GW9662 group: Identical
to ischemia model group except for receiving
GW9662 (Alexis, USA) 5 μg, i.c.v. [29], at 30 min
prior to artery occlusion and rosiglitazone 7.2 mg/kg
i.p. at 1 hour prior to artery occlusion (n = 12).
7. GW9662 in sham control group: Identical to sham
group except for receiving GW9662 5 μg, i.c.v.,
at 30 min prior to sham surgery (n = 12).
GCIRI animal model
Rats were anesthetized with 4% chloral hydrate (40 mg/
100 g of body weight). A midline incision (3 cm) was
made in the neck to expose the common carotid vein on
the right side and the common carotid artery on both
sides. A tubing was inserted via the common carotid
vein into the right atrium, and 500 U of heparin were
infused. About 30% of the total blood volume was col-
lected. The common carotid artery on both sides were
occluded for 20 min prior to autologous transfusion of
the collected blood prior to artery occlusion. The rightcommon carotid vein was ligated and the incision was
closed. The sham operation consisted of similar procedures
but the common carotid arteries were not occluded
[24,30,31]. Body temperature of the rats was maintained
at 37.5 ± 0.5°C by the use of a heating pad during the
period of ischemia and the following 2 h.
SLM tests
SLMs were tested using a Morris water maze on the
seventh day after the artery occlusion for 5 days (i.e.,
day 8-day 12 post-GCIRI), following a reported method
[32]. The training process consisted of two steps. In step 1
(day 1), the rats were placed on the platform for 1 min,
and then were made to swim freely to the platform. If the
rats did not reach the platform within 3 min, they were
guided to the platform manually by the researchers. On
days 2–4, the training consisted of four sessions per day.
A different entry site was used for each daily session, and
the rats were placed underwater to search for the plat-
form. If the rats did not reach the platform within 3 min,
they were guided to the platform by the researchers and
allowed to stay there for 10 sec. The maximum search
time was set at 3 min. In step 2 (day 5), the platform was
removed, and the rats were placed in the entry site where
the last training was performed. The latency was recorded
with a maximum of 3 min.
Histopathological and IHC examinatios
Rats were anesthetized with 4% chloral hydrate (40 mg/
100 g) prior to perfusion with 4% paraformaldehyde. The
brains were removed and stored in 4% paraformaldehyde.
Brain sections (each 5-μm) were prepared for staining
with hematoxylin-eosin (HE). The morphology of hip-
pocampal neurons and changes at the cellular level were
observed.
An immunohistochemical method was used to test the
expression of the NF-κB p65 protein. The sections were
obtained from the same paraffin blocks as used for
histological evaluation. High pressure antigen retrieval
was performed in citrate buffer for 10 min prior to perox-
idase quenching with 3% H2O2 in phosphate-buffered
saline (PBS) for 10 min. The sections were then washed
in water and preblocked with normal goat serum for
10 min. Then, slides were incubated with a rabbit poly-
clonal antibody raised against NF-κB p65 (1:50, Santa
Cruz, CA) [24] overnight at 4°C. The sections were
then incubated with biotinylated secondary antibodies
(1:400, BIO-LAB, China) [33] for 20 min. Following a
washing step with PBS, the avidin-biotin complex was
applied. Finally, the sections were rinsed in PBS, devel-
oped with diaminoben-zidine tetrahydrochloride substrate
for 3 min and counterstained with hematoxylin. The
Integral Optical Density (IOD) were analyzed by image-pro
plus 6.0 software.
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of PPARs mRNA
Total RNA was extracted from hippocampal tissue using
TRIzol reagent (BioFlux). The RT-PCR system included
1 μg total RNA, 1 μmol/L oligo(dT), 0.2 mmol/L dNTPs,
10 U RNase inhibitor and 4 U ReverTra Ace (FSK-100,
Toyobo). The reaction consisted of 20 min at 42°C, 5 min
at 99°C and then 5 min at 4°C. The primers of PPARs
were designed using Primer Premier 5.0 (Premier Biosoft
International, Palo Alto, California, USA) on the basis
of the rat PPARs cDNA sequence in genebank and synthe-
sized by Sangon Biotech Co., Ltd. (Shanghai, China). The
primers of endogenous β-Actin were purchased from
DINGGUO Biotech Incorporated Company (Beijing,
China). The primers were: for PPAR-α, forward (F): 5'-A
CGATGCTGTCCTCCTTGATG-3', reverse (R): 5'-GCG
TCTGACTCGGTCTTCTTG-3'; for PPAR-β, F: 5'-GCC
GCCCTACAACGAGATCA-3'; R: 5'-CCACCAGCAGTC
CGTCTTTGT-3; for PPAR-γ, F: 5'-CCCTTTACCACG
GTTGATTTCTC-3', R: 5'-GCAGGCTCTACTTTGATC
GCACT-3'. Primers for β-actin were purchased from
Beijing Dingguo Biotechnology: F: 5'-GTGGGGCGCC
CCAGGCACCA-3'; R: 5'-CTTCCTTAATGTCACGCA
CGATTTC-3'. Amplification was carried out in 0.2 mmol/L
dNTPs, 2 mmol/L MgCl2, 1 μmol/L of each primer, and
2.5 U Taq DNA polymerase (Promega), and consisted of
the following steps: initial denaturation at 94°C for 4 min,
followed by 35 cycles of 94°C for 15 sec, 53.1°C for 15 sec
and 72°C for 40 sec, annealing at 55.2–57°C (at 55.2, 57.0
and 53.1°C for PPAR-α, R-β and -γ respectively for
15 sec), and a final extension at 72°C for 5 min. The
amplified products were separated with 2% agarose gel
electrophoresis. The optical density of PPAR-γ was de-
termined with Quantity One software (Bio-Rad), and
expressed as the ratio against β-actin.Figure 1 Effects of rosiglitazone on spatial learning and memory func
##: P < 0.05 and 0.01 vs. IR.PPARs western blot
Hippocampal tissue (50 mg) was homogenized in 0.5 ml
tissue lysate and centrifugated at 12,000 g at 4°C for 5 min.
The supernatant was (20 μg protein) was subjected to so-
dium dodecyl sulfate polyacrylamide gel electrophoresis
(SDS-PAGE) and electrotransferred to polyvinylidene fluor-
ide (PVDF) membranes. The membranes were blocked
in 5% nonfat milk for 1 hour at room temperature. After
washing in phosphate buffer solution (PBS) for 3 times, the
membrane was incubated with a rabbit-anti-rat PPAR-α
antibody (1:1000; Abcam, England) [30], PPAR-β antibody
(1:1000; Santa Cruz, CA) [24], PPAR-γ antibody (1:1000;
Abcam, England ) [30] at room temperature overnight, and
then incubated with an anti-rabbit IgG conjugated with
horseradish peroxidase (1:1000; Santa Cruz, CA) at 37°C
for 1 hour. The color reaction was carried out using ECL
reagents (Pierce, USA). A Bio-Rad imaging system was used
to quantify the PPARs band.
Biochemical analysis of hippocampal tissues
Hippocampal tissue was homogenized with physiological sa-
line at a ratio of 1:9 (weight/volume) in a glass homogenizer.
The homogenate was centrifuged at 3,000 rpm for 10 min,
and the supernatant was collected to determine superoxide
dismutase (SOD) activity using an SOD reagent (Nanjing
Jiancheng Bioengineering Institute, China) and to deter-
mine the malondialdehyde (MDA) content using a MDA
kit (Nanjing Jiancheng Bioengineering Institute). The levels
of inflammatory cytokines (TNF-α, IL-1β, IL-6 and IL-10)
were measured using ELISA kits (ADI, Stamford, USA).
Statistical analysis
All data are expressed as mean ± SD, and analyzed using
Statistical Package for the Social Sciences v. 12.0 (SPSS
12.0, SPSS Inc., Chicago, IL, USA). Differences amongtion (n = 12). * and **: P < 0.05 and 0.01, vs. sham control; # and
Figure 2 Effects of rosiglitazone on hippocampal neurons in rats with global cerebral IRI (HE stain, ×400, n = 3). A: Representative
pictures of H&E stained CA1 sections on Day 12 post-IRI shown at 400 × magnification. Scale bars = 50 μm. B: Group data showing the effect
of rosiglitazone on the cell death rate. ##P < 0.01 compared with vehicle sham group; *P < 0.05 **P < 0.01 compared with the IR group;
ΔΔP < 0.05 compared with 7.2 mg/kg ROS group; ●●P < 0.05 compared with 7.2 mg/kg ROS plus GW9662 group.
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(ANOVA), Student Newman Keuls (SNK) and SNK-q
tests. Results were considered significant if the two-tailed
P was <0.05.Results
Effect of rosiglitazone on learning and memory
Relative to the sham controls, rats with GCIRI had signifi-
cantly longer platform-seeking time during the training
Table 2 Effects of rosiglitozane on MDA content and SOD
activity (n = 5)
Group SOD MDA
(ng/ml) (ng/ml)
sham control 71.58 ± 6.23 1.74 ± 0.14
IR 37.24 ± 5.16** 2.33 ± 0.19**
0.8 mg/kg Ros 40.37 ± 4.32** 2.14 ± 0.15**
2.4 mg/kg Ros 49.37 ± 7.25**## 1.97 ± 0.17*##
7.2 mg/kg Ros 55.47 ± 9.31## 1.89 ± 0.21##
7.2 mg/kg Ros plus GW9662 35.31 ± 6.11** 2.44 ± 0.17**
GW9662 in sham control 69.43 ± 4.57 1.83 ± 0.24
Datas are expressed as mean ± SD (n = 5). * and **:P < 0.05 and 0.01, vs. sham
control; # and ##:P < 0.05 and 0.01 vs. IR.
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Rosiglitazone dose-dependently reduced the platform-
seeking time in the learning and memory phases in rats
with GCIRI. GW9662 attenuated the effects of rosiglita-
zone, but no significant difference was observed between
the sham control and the GW9662 in sham control
groups (Figure 1).
Histopathological changes
GCIRI resulted in robust nuclear pyknosis and a reduction
in the number of neurons in the hippocampus. In rats
pretreated with 7.2 mg/kg rosiglitazone, hippocampal
neurons were clear and intact in structure, and cells were
aligned properly. Nuclear pyknosis was evident in the
hippocampus of rats pretreated with 0.8 or 2.4 mg/ rosigli-
tazone. GW9662 attenuated effects of rosiglitazone on
nuclear pyknosis, but no significant difference was found
between the sham control and the GW9662 in sham con-
trol groups (Figure 2).
Levels of IL-1β, IL-6, IL-10 and TNF-α
GCIRI increased the levels of inflammatory cytokines
IL-1β, IL-6 and TNF-α in the hippocampus. The IL-10
level was markedly decreased. Rosiglitazone, in a dose-
dependent manner, attenuated I/R-induced elevation of
TNF-α, IL-1β and IL-6 levels and the reduction of IL-10.
The effects of rosiglitazone were inhibited by GW9662. No
significant difference was observed between the sham con-
trol and the GW9662 in sham control groups (Table 1).
MDA levels and SOD activity
Global cerebral I/R resulted in significant increases of
MDA content and a decrease in SOD activity in the
hippocampus compared to the sham control group. Rosi-
glitazone attenuated I/R-induced elevation of MDA levels
and reduction of SOD activity. The effects of rosiglitazone
were inhibited by GW9662, but there was no significant
difference between the sham control and the GW9662 in
sham control groups (Table 2).Table 1 Effects of rosiglitozane on IL-1b,IL-6,IL-10 and TNF-a
Group IL-1β IL
(mg/ml) (n
sham control 218.35 ± 42.2 6
IR 561.31 ± 49.98** 1
0.8 mg/kg Ros 505.11 ± 39.28** 1
2.4 mg/kg Ros 437.71 ± 51.74**## 1
7.2 mg/kg Ros 390.22 ± 42.08## 8
7.2 mg/kg Ros plus GW9662 572.40 ± 33.27** 1
GW9662 in sham control 233.57 ± 28.33 6
Datas are expressed as mean ± SD (n = 5). * and **:P < 0.05 and 0.01, vs. sham conNF-κB p65 expression
IHC results revealed a significant increase of NF-κB p65
expression in hippocampal neuronal cytoplasm. Rosiglita-
zone decreased the expression of NF-κB p65 protein in
rats subjected to GCIRI. Such an effect was attenuated by
GW9662, but there was no significant difference between
the sham control and the GW9662 in sham control groups
(Figure 3).PPAR-α, PPAR-β and PPAR-γ mRNA
GCIRI resulted in significant increases in PPAR-α, PPAR-β
and PPAR-γ mRNAs compared with that of the model
control group (p < 0.01). Rosiglitazone at 0.8, 2.4 and
7.2 mg/kg inhibited the increase of the PPAR-γ mRNA ex-
pression (p < 0.05, <0.01 and <0.01, respectively), with an
inhibition rate of 10.79%, 20.63% and 32.33%, respectively,
in a dose-dependent manner. PPAR-α and PPAR-β were
not affected. GW9662 had no significant effect on the ex-
pression of PPARs in the sham control group (Figure 4).PPAR-α, PPAR-β and PPAR-γ proteins
GCIRI resulted in significant increases in the protein levels
of PPAR-α, PPAR-β and PPAR-γ. Rosiglitazone decreasedcontent (n = 5)
-6 IL-10 TNF-α
g/ml) (ng/ml) (ng/ml)
.37 ± 0.43 3.01 ± 0.25 2.19 ± 0.35
5.83 ± 1.37* 1.86 ± 0.15** 6.36 ± 1.11**
3.27 ± 0.89** 2.81 ± 0.37** 5.57 ± 0.43**
0.27 ± 0.516**## 2.37 ± 0.25**## 4.23 ± 0.61**##
.05 ± 0.95## 2.01 ± 0.31## 3.39 ± 0.37##
6.17 ± 1.12** 1.95 ± 0.17** 6.19 ± 1.01**
.07 ± 0.33 3.21 ± 0.35 2.45 ± 0.22
trol; # and ##:P < 0.05 and 0.01 vs. IR.
Figure 3 Effects of rosiglitazone on NF-κB expression in hippocampal tissues of rats with global cerebral IRI (HE stain, ×400, n = 3). A:
representative images of the hippocampal CA1 region after IRI. (Scale bars = 50 μm). B: Group data showing the effect of rosiglitazone on NFκB
expression and translocation. #P < 0.05 compared with sham control group; *P < 0.05 **P < 0.01 compared with the IR group; ΔP < 0.05
compared with 7.2 mg/kg ROS group.
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in a dose-dependent way. PPAR-α and PPAR-β were not
affected, and there was no significant difference between
the sham control and the GW9662 in sham control
groups (Figure 5).Discussion
GCIRI occurs in patients who are successfully resuscitated
from various clinical conditions such as cardiac arrest,
asphyxia and shock, because of the limited therapeutic
window (2–3 h after onset of the symptoms), but very
Figure 4 Effects of rosiglitazone on expression of PPARs (A, PPAR-α; B, PPAR-β; C, PPAR-γ) mRNA in hippocampus of rats with global
cerebral IRI. Lane 1, sham control; Lane 2, IR ; Lane 3, 0.8 mg/kg ROS; Lane 4, 2.4 mg/kg ROS; Lane 5, 7.2 mg/kg ROS; Lane 6, 7.2 mg/kg ROS
plus GW9662; Lane 7, GW9662 in sham control. *and **P < 0.05 and 0.01, VS sham control, # and ##P < 0.05 and 0.01, VS IS group. (n = 4).
Luo et al. Behavioral and Brain Functions 2014, 10:21 Page 8 of 11
http://www.behavioralandbrainfunctions.com/content/10/1/21few patients with cardiac arrest receive timely and effect-
ive treatment. Therefore, it is of great importance to inves-
tigate the molecular mechanisms of such injury caused by
ischemic cerebrovascular disease, and thereby to develop
effective drugs for treatment.
Our study showed that GCIRI induced inflammation
and oxidative stress in the hippocampus of rats. In the
hippocampus of rats undergoing GCIRI, the expression
of PPARs and the level of NF-κB increased. Rosiglitazone
attenuated the damage of hippocampal neurons and im-
proved SLM functions. Such effects were attenuated by
the PPAR-γ antagonist GW9662. Our results suggest that
PPAR-γ agonists produce anti-inflammatory action by
inhibiting the activation of the NF-κB signaling pathway
and the expressions of inflammatory factors. Intriguingly,
neither the agonist nor the antagonist of PPAR-γ had any
effect on the expression of PPAR-α and PPAR-β.
Recent reports show that PPARs have a neuroprotec-
tive effect on the CNS. Fibrates as PPAR-α ligands have
antioxidant and anti-inflammatory effects on GCIRI of
female rats, and pretreatment with gemfibrozil prior to
I/R can modulate inflammatory factors and stimulate the
antioxidant defense system [34]. In an experimental model
of spinal cord injury in mice, simvastatin can inhibit theseverity or level of spinal cord inflammation, neutrophil
infiltration, pro-inflammmatory cytokine expression and
apoptosis [35]. In addition, PPAR-β has become a focus in
the field of neuronal damage. Compared with the wild
type, the PPAR-β-null mice exhibit a significantly larger
size of infarct in a model of focal cerebral ischemia estab-
lished by MCAO [36,37]. Preactivation of PPAR-β could
dose-dependently improve SLM function and cytomor-
phological change of the hippocampal neurons in the rats
with GCIRI [24].
In a previous study on rats, intraventricular adminis-
tration of pioglitazone at 1 h before and 24 h after
MCAO separately reduced the infarct area and improved
neurological function [38]. Another study demonstrated
that in cultured astrocytes and microglia, the expressions
of lipopolysaccharide (LPS)-induced IL-6, TNF-α, iNOS,
and COX-2 were elevated. The PPAR-γ agonists thiadia-
zolidinones up-regulate the expression of LPS-induced
iNOS, and reduce the productions of NO, IL-6 and TNF-α
in a culture. The neuroprotective effects of thiadiazolidi-
nones were abolished by GW9662 [39,40]. Treatment with
PPAR-γ agonists before MCAO decreases the expressions
of ROS and iNOS, decreases lipid peroxidation and re-
verses glutathione (GSH) exhaustion in the hippocampus
Figure 5 Effects of rosiglitazone on expression of PPARs (A, PPAR-α; B, PPAR-β; C, PPAR-γ) proteins in hippocampus of rats with global
cerebral IRI. Lane 1, sham control; Lane 2, IR ; Lane 3, 0.8 mg/kg ROS; Lane 4, 2.4 mg/kg ROS; Lane 5, 7.2 mg/kg ROS; Lane 6, 7.2 mg/kg ROS
plus GW9662; Lane 7, GW9662 in sham control. *and **P < 0.05 and 0.01, VS sham control, # and ##P < 0.05 and 0.01, VS IR group. (n = 4).
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COX-2 in the primary cortical neurons and prevents neur-
onal apoptosis induced by oxidative stress [42]. A more
recent investigation of the effects of PPAR-γ agonists
on the NF-κB signaling pathway [43]showed that upon
MCAO, the p65 subunit of NF-κB was transferred from
the cytoplasm to the nucleus of the hippocampal neurons.
Treatment with pioglitazone subdued the transferrence of
the NF-κB p65 subunit to the nucleus. These findings are
consistent with our observations and indicate that PPAR-γ
agonists are neuroprotective against GCIRI.
The above results indicate that PPAR-α, −β and especially
PPAR-γ may be important targets for GCIRI research and
drug therapy. Although many studies have reported I/R can
induce the increased PPAR-γ expression [44,45], it is un-
known whether the inhibition or activation of the PPAR-γ
has any effect on the expression of PPAR-α and -β. This
study shows that the expression of PPAR-γ in the hippo-
campus of GCIRI rats increased, and the expressions of
PPAR-α and -β also increased. Moreover, agonists and
antagonists given to PPAR-γ had no obvious effect on the
expression of PPAR-α or -β, suggesting that PPAR-α, −β
and -γ act in separate pathways. The intervention of
GCIRI by changing the activity or expression of PPAR-γ
resulted in minimal side effects from the PPAR-α and -β
expression. Moreover, since PPAR-α, −β and -γ were three
independent pathways, and since the activation or expres-
sion of all of them could protect neurons by reducing
neuronal inflammation and oxidative stress injury, a
superimposed effect may be produced if the three are
activated or expressed at the same time. Such hypotheseswill be verified in the following experiment to provide
new ideas and experimental basis for combined therapy
for cerebral ischemic injury by using PPAR-α, −β and -γ
agonists.
Conclusions
The present study demonstrated that the activation or
antagonism of PPAR-γ has no effect on the expression
of PPAR-α or -β in the hippocampus of rats with GCIRI,
and the three PPAR isotypes act in three independent
pathways in the CNS.
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